Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17675261 | 0.82 | BACE1 (0.52) | BACE1KCNH2 | |
| SCHEMBL17675694 | 0.77 | BACE1 (0.44) | BACE1TAAR1APP | |
| SCHEMBL17679230 | 0.75 | BACE1 (0.53) | BACE1KCNH2APP | |
| SCHEMBL17675266 | 0.70 | BACE1 (0.41) | BACE1KCNH2TAAR1 | |
| SCHEMBL8534926 | 0.69 | BACE1 (0.41) | BACE1 | |
| SCHEMBL9932928 | 0.69 | BACE1 (0.41) | BACE1TAAR1 | |
| SCHEMBL17679236 | 0.68 | BACE1 (0.40) | BACE1KCNH2TAAR1 | |
| SCHEMBL9932295 | 0.65 | BACE1 (0.70) | BACE1 | |
| SCHEMBL9882532 | 0.65 | BACE1 (0.70) | BACE1 | |
| SCHEMBL8514168 | 0.65 | BACE1 (0.66) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10053453-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2018-08-21 | — | — | US | disclosed |
| US-20170313686-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313686-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313686-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2017-11-02 | — | — | US | disclosed |
| WO-2016055858-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055858-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313686-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885KCNH2 4739/4885TAAR1 1924/4885 |
| US-10053453-B2 | Compounds and their use as BACE inhibitors | BACE1, BACE2, APP | BACE1 1/4885KCNH2 4739/4885TAAR1 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.